Shareholding disclosure

Rudolf Maag

Declared position

Threshold

Fell below threshold

Timeline

Published

12.06.2014

Transaction

03.06.2014

Voting rights breakdown

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

Notice details

CategoryGroup of shareholders

ExchangeXSWX

Notification ID

TBE6B00036

Beneficial owner

Rudolf Maag

Declared address

Rudolf Maag, 4102 Binningen

The beneficiary in Part 1 controls the direct seller in Part 2

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Rudolf Maag

Santhera Pharmaceuticals Holding AG12.06.2014TBE6B00036

Disclosure summary

Rudolf Maag disclosed a holding in Santhera Pharmaceuticals Holding AG that fell below the publication threshold, published by SIX Exchange Regulation on 12.06.2014, at 3% of voting rights. Notice category: Group of shareholders.

Disclosed position

Below threshold

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Rudolf Maag disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 12.06.2014.

Publication date12.06.2014

Transaction date03.06.2014

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerRudolf Maag

Declared addressRudolf Maag, 4102 Binningen

CategoryGroup of shareholders

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

ExchangeXSWX

Notification IDTBE6B00036

Conditions

The beneficiary in Part 1 controls the direct seller in Part 2

Source: SIX Exchange Regulation · Publication date: 12.06.2014

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open